• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 489
  • 217
  • 215
  • 60
  • 35
  • 32
  • 28
  • 25
  • 24
  • 18
  • 14
  • 13
  • 8
  • 5
  • 3
  • Tagged with
  • 1369
  • 156
  • 147
  • 124
  • 112
  • 110
  • 103
  • 102
  • 93
  • 91
  • 90
  • 86
  • 76
  • 75
  • 75
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
271

Epigallocatechin Gallate in the Regulation of Insulin Secretion

Yuskavage, Julia Kathryn 06 June 2008 (has links)
In both Type 1 diabetes (T1D) and Type 2 diabetes (T2D), inadequate beta-cell mass and beta-cell dysfunction lead to impaired insulin secretion, and ultimately worsen glycemic control. Green tea has drawn wide attention due to its possible health-promoting properties, including enhancement of beta-cell function. We assessed the acute and relative long-term effects of epigallocatechin gallate (EGCG) on insulin secretion and synthesis from clonal beta-cells (INS1E cells), rat islets, and human islets, using 0.1, 1, or 5 µM. We determined if EGCG decreased blood glucose in healthy rats acutely, using 50 or 150 mg/kg body weight (BW), and after 12 days of supplementation in drinking water, using 0.1% and 0.5%. In the in vitro studies, EGCG significantly potentiated glucose-stimulated insulin secretion (GSIS) in rat islets (at 0.1, 1, and 5 µM) and human islets (at 1 µM), and elevated insulin content within INS1E cells (at 0.1, 1, and 5 µm) and human islets (at 1 µM), (P<0.05). Nutritional supplementation of EGCG (0.5% in drinking water) for 12 days in healthy rats significantly increased insulin synthesis, compared to that of controls, from 0.2 ± 0.02 to 1.4 ± 0.2 ng/mg protein, without alteration of insulin secretion in isolated islets (P<0.05). These findings demonstrate that EGCG may play a role in the regulation of pancreatic beta-cell function, thereby contributing to an anti-diabetic effect of this agent. / Master of Science
272

Stabilized low-n amyloid-ß oligomers induce robust novel object recognition deficits associated with inflammatory, synaptic, and GABAergic dysfunction in the rat

Watremez, W., Jackson, J., Almari, B., McLean, Samantha, Grayson, B., Neilla, J.C., Fischer, N., Allouche, A., Koziel, V., Pillot, T., Harte, M.K. 06 February 2018 (has links)
Yes / Background:With current treatments for Alzheimer’s disease (AD) only providing temporary symptomatic benefits, disease modifying drugs are urgently required. This approach relies on improved understanding of the early pathophysiology of AD. A new hypothesis has emerged, in which early memory loss is considered a synapse failure caused by soluble amyloid-β oligomers (Aβo). These small soluble Aβo, which precede the formation of larger fibrillar assemblies, may be the main cause of early AD pathologies. Objective:The aim of the current study was to investigate the effect of acute administration of stabilized low-n amyloid-β1-42 oligomers (Aβo1-42) on cognitive, inflammatory, synaptic, and neuronal markers in the rat. Methods:Female and male Lister Hooded rats received acute intracerebroventricular (ICV) administration of either vehicle or 5 nmol of Aβo1-42 (10μL). Cognition was assessed in the novel object recognition (NOR) paradigm at different time points. Levels of inflammatory (IL-1β, IL-6, TNF-α), synaptic (PSD-95, SNAP-25), and neuronal (n-acetylaspartate, parvalbumin-positive cells) markers were investigated in different brain regions (prefrontal and frontal cortex, striatum, dorsal and ventral hippocampus). Results:Acute ICV administration of Aβo1-42 induced robust and enduring NOR deficits. These deficits were reversed by acute administration of donepezil and rolipram but not risperidone. Postmortem analysis revealed an increase in inflammatory markers, a decrease in synaptic markers and parvalbumin containing interneurons in the frontal cortex, with no evidence of widespread neuronal loss. Conclusion:Taken together the results suggest that acute administration of soluble low-n Aβo may be a useful model to study the early mechanisms involved in AD and provide us with a platform for testing novel therapeutic approaches that target the early underlying synaptic pathology.
273

Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor

Liakouli, V., Elies, Jacobo, El-Sherbiny, Y.M., Scarcia, M., Grant, G., Abignano, G., Derrett-Smith, E.C., Esteves, F., Cipriani, P., Emery, P., Denton, C.P., Giacomelli, R., Mavira, G., Del Galdo, F. 2017 December 1919 (has links)
Yes / Objectives Systemic sclerosis (SSc) is characterised by tissue fibrosis and vasculopathy with defective angiogenesis. Transforming growth factor beta (TGF-β) plays a major role in tissue fibrosis, including downregulation of caveolin-1 (Cav-1); however, its role in defective angiogenesis is less clear. Pigment epithelium-derived factor (PEDF), a major antiangiogenic factor, is abundantly secreted by SSc fibroblasts. Here, we investigated the effect of TGF-β and Cav-1 on PEDF expression and the role of PEDF in the ability of SSc fibroblasts to modulate angiogenesis. Methods P EDF and Cav-1 expression in fibroblasts and endothelial cells were evaluated by means of immunohistochemistry on human and mouse skin biopsies. PEDF and Cav-1 were silenced in cultured SSc and control fibroblasts using lentiviral short-hairpin RNAs. Organotypic fibroblast–endothelial cell cocultures and matrigel assays were employed to assess angiogenesis. Results P EDF is highly expressed in myofibroblasts and reticular fibroblasts with low Cav-1 expression in SSc skin biopsies, and it is induced by TGF-β in vitro. SSc fibroblasts suppress angiogenesis in an organotypic model. This model is reproduced by silencing Cav-1 in normal dermal fibroblasts. Conversely, silencing PEDF in SSc fibroblasts rescues their antiangiogenic phenotype. Consistently, transgenic mice with TGF-β receptor hyperactivation show lower Cav-1 and higher PEDF expression levels in skin biopsies accompanied by reduced blood vessel density. Conclusions O ur data reveal a new pathway by which TGF-β suppresses angiogenesis in SSc, through decreased fibroblast Cav-1 expression and subsequent PEDF secretion. This pathway may present a promising target for new therapeutic interventions in SSc. / NIHR CDF; EULAR ODP
274

Transforming growth factor beta (TGF-β) isomers influence cell detachment of MG-63 bone cells

Sefat, Farshid, Khaghani, Seyed A., Nejatian, T., Genedy, Mohamed A., Abdeldayem, Ali I.A., Moghaddam, Z.S., Denyer, Morgan C.T., Youseffi, Mansour 20 August 2015 (has links)
No / Bone repair and wound healing are modulated by different stimuli. There is evidence that Transforming Growth Factor-beta (TGF-β) super-family of cytokines have significant effects on bone structure by regulating the replication and differentiation of chondrocytes, osteoblasts and osteoclasts. There is also significant evidence that interactions with extracellular matrix molecules influence cell behaviour. In this study cell surface attachment was examined via a trypsinization assay using various TGF-β isomers in which the time taken to trypsinize cells from the surface provided a means of assessing the strength of attachment. Three TGF-β isomers (TGF-β1, 2 and 3), four combined forms (TGF-β(1 + 2), TGF-β(1 + 3), TGF-β(2 + 3) and TGF-β(1 + 2 + 3)) along with four different controls (BSA, HCl, BSA/HCl and negative control) were investigated in this study. The results indicated that treatment with TGF-β1, 2, 3 and HCl decreased cell attachment, however, this effect was significantly greater in the case of TGF-β3 (p < 0.001) indicating perhaps that TGF-β3 does not act alone in cell detachment, but instead functions synergistically with signalling pathways that are dependent on the availability of hydrogen ions. Widefield Surface Plasmon Resonance (WSPR) microscope was also used to investigate cell surface interactions.
275

Protein deregulation associated with breast cancer metastasis

Chan, K.K., Matchett, K.B., McEnhill, P.M., Dakir, El-Habib, McMullin, M.F., El-Tanani, Y., Patterson, Laurence H., Faheem, A., Rudland, P.S., McCarron, P.A., El-Tanani, Mohamed 2015 May 1931 (has links)
No / Breast cancer is one of the most prevalent malignancies worldwide. It consists of a group of tumor cells that have the ability to grow uncontrollably, overcome replicative senescence (tumor progression) and metastasize within the body. Metastases are processes that consist of an array of complex gene dysregulation events. Although these processes are still not fully understood, the dysregulation of a number of key proteins must take place if the tumor cells are to disseminate and metastasize. It is now widely accepted that future effective and innovative treatments of cancer metastasis will have to encompass all the major components of malignant transformation. For this reason, much research is now being carried out into the mechanisms that govern the malignant transformation processes. Recent research has identified key genes involved in the development of metastases, as well as their mechanisms of action. A detailed understanding of the encoded proteins and their interrelationship generates the possibility of developing novel therapeutic approaches. This review will focus on a select group of proteins, often deregulated in breast cancer metastasis, which have shown therapeutic promise, notably, EMT, E-cadherin, Osteopontin, PEA3, Transforming Growth Factor Beta (TGF-β) and Ran.
276

β-Diketonate Titanium Compounds Exhibiting High In Vitro Activity and Specific DNA Base Binding

Lord, Rianne M., Mannion, J.J., Crossley, B.D., Hebden, A.J., McMullon, M.W., Fisher, J., Phillips, Roger M., McGowan, P.C. 23 November 2016 (has links)
Yes / Herein, we report 31 new β-diketonate titanium compounds of the type [Ti(O,O)2X2], whereby O,O = asymmetric or symmetric β-diketonate ligand and X = Cl, Br, OEt or OiPr. Thirteen new crystal structures are discussed and show that these octahedral species all adopt cis geometries in the solid state. These compounds have been tested for their cytotoxicity using SRB and MTT assays, showing several of the compounds are as potent as cisplatin against a range of tumour cell lines. Results also show the [Ti(O,O)2Br2] complexes are more potent than [Ti(O,O)2Cl2], [Ti(O,O)2(OEt)2] and [Ti(O,O)2(OiPr)2]. Using a simple symmetrical heptane-3,5-dione (O,O) ligand bound to titanium, we observed more than a 50-fold increase in potency with the [Ti(O,O)2Br2] (28) when compared to [Ti(O,O)2Cl2] (27). One of the more potent compounds (6) has been added to three different sixmers of DNA, in order to analyse the potential DNA binding of the compound. NMR studies have been carried out on the compounds, in order to understand the structural properties and the species formed in solution during the in vitro cell assays.
277

Wnt Signaling as a Therapeutic Target in Cancer and Metastasis

Morgan, Richard, Ankrah, R., El-Tanani, S., Patterson, Laurence H., Loadman, Paul, Rudland, P.S., El-Tanani, Mohamed 06 January 2017 (has links)
No / Wnt signaling normally functions in cell determination and proliferation and is essential for embryonic development. It does this by regulating target genes through a tightly regulated but complex signaling cascade. Overexpression of these genes due to aberrant Wnt activity can lead to uncontrolled cell growth and survival, and ultimately oncogenesis. Wnt signaling is also involved in epithelial–mesenchymal transition that contributes to tumor progression and metastasis evidence that tumor growth can be suppressed irrespective of other neoplastic promoters when the Wnt pathway is blocked and this has led to interest in its use as a therapeutic target. Recent developments in our understanding of the Wnt signaling cascade have led to research into drugs that specifically target different levels in this pathway, and the identification of β-catenin as the primary cause of dysregulated Wnt signaling has led to a number of protein knockdown strategies. Moreover, increased knowledge of the 300–400 Wnt inducible genes has provided a large untapped source of new potential therapeutic targets. Existing drugs such as nonsteroidal anti-inflammatory drugs and vitamin A and D derivatives have also shown efficacy in disrupting the Wnt signaling pathway and, together with a new generation of derivatives, they may soon be in clinical trials. This chapter details the Wnt signaling pathway, its role in different cancers, and some potential therapeutic targets that may show promise as effective cancer treatments.
278

Stereoselective production of dimethyl-substituted carbapenams via engineered carbapenem biosynthesis enzymes

Hamed, Refaat B., Henry, L., Claridge, T.D.W., Schofield, C. 2016 December 1928 (has links)
Yes / Stereoselective biocatalysis by crotonase superfamily enzymes is exemplified by use of engineered 5-carboxymethylproline synthases (CMPSs) for preparation of functionalized 5-carboxymethylproline (5-CMP) derivatives methylated at two positions (i.e. C2/C6, C3/C6 and C5/C6), including products with a quaternary centre, from appropriately-substituted-amino acid aldehydes and C-2 epimeric methylmalonyl-CoA. The enzymatically-produced disubstituted 5-CMPs were converted by carbapenam synthetase into methylated bicyclic Β-lactams, which manifest improved hydrolytic stability compared to the unsubstituted carbapenams. The results highlight the use of modi-fied carbapenem biosynthesis enzymes for production of new carbapenams with improved properties. / Medical Research Council, Biotechnology and Biological Sciences Research Council (BB/L000121/1)
279

Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Sharmin, Nahid, Nganwuchu, Chinyere C., Nasim, Md. Talat 23 May 2021 (has links)
Yes / Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches. / Research carried out at Nasim laboratories is funded by GrowMedtech, the Royal Society, the Commonwealth Scholarship Commission (CSC) and the University of Bradford (UoB). N.S. is funded by the CSC and C.C.N. is partly funded by the UoB.
280

Etude du rôle des espèces réactives de l'oxygène dans le développement du pancréas / Role of reactive oxygen species during pancreas development

Hoarau, Emmanuelle 30 March 2015 (has links)
Le pancréas est un organe hétérogène composé d’une partie exocrine, responsable de la synthèse d’enzymes pour la digestion, et d’une partie endocrine, essentielle pour l’homéostasie glucidique. Notamment la sécrétion d’insuline par les cellules β contrôle la glycémie. Les dysfonctionnements des cellules β sont une des causes du diabète, première épidémie non infectieuse au monde. Il est actuellement possible d’en traiter les symptômes mais pas de le guérir. De nombreux laboratoires recherchent un protocole idéal de production de cellules β afin de pouvoir greffer ces cellules aux patients. L’identification des facteurs qui gouvernent chaque étape du développement des cellules β devrait permettre de progresser dans ce sens. Le but de ma thèse a été d’étudier le rôle des Espèces Réactives de l’Oxygène (ROS) au cours du développement pancréatique. Cette question a été soulevée lorsque nous avons analysé l’expression des gènes codant pour les enzymes détoxifiantes des ROS: leur expression était extrêmement réduite dans les pancréas embryonnaires comparés aux pancréas adultes, suggérant que les précurseurs sont particulièrement sensibles aux variations des ROS. Nous avons ensuite montré que la réduction des ROS in vivo, obtenue par un traitement avec un antioxydant (NAC), diminue le développement des cellules β. Une analyse in vitro a permis de détailler les mécanismes de l’action des ROS. En effet, le peroxyde d’hydrogène favorise la différenciation des cellules β en augmentant l’expression du facteur pro-endocrine Ngn3 dans les progéniteurs. Ce processus implique l’activation la voie ERK1/2 par les ROS. Au contraire, la diminution des ROS induite par des méthodes génétiques ou pharmacologiques altère la différenciation des cellules β. Nos résultats indiquent également que la mitochondrie est impliquée dans ce processus. Nous avons donc montré que la présence des ROS est essentielle pour le bon développement du pancréas. Ces recherches devraient donc permettre de progresser vers une thérapie cellulaire du diabète. / The pancreas is an heterogenous gland composed by exocrine tissue, responsible for digestive enzyme secretions, and endocrine tissue, essential for glucose homeostasis. In particular β cells secrete insulin which controls glycemia. Moreover, β cell failure is one of the primary causes of diabetes and this pathology is nowadays considered as the first non infectious worldwide outbreak. There is unfortunately no cure for this disease. Many laboratories are currently improving β cell generation protocols in order to inject those cells into patients. This is the reason why it appears mandatory to be able to identify factors that govern each step of β cell development. The aim of my work was to study the role of the Reactive Oxygen Species (ROS) during pancreatic development. First we found out that the expression of genes coding for antioxidant enzymes was extremely low in embryonic pancreas compared to adult pancreas. This suggested that progenitors could be sensitive to ROS variations. We then showed in vivo using an antioxidant component (NAC) that decreasing ROS level diminishes β cell development. Analysis in vitro allowed us to better describe the role of ROS. Indeed, hydrogen peroxyde favors β cell differentiation by increasing the pro-endocrine marker NGN3 expression in the progenitors. In this process, ROS activate the ERK1/2 signaling pathway. On the contrary, lowering ROS level using both pharmacologic and genetic approaches, decreases β cell differentiation. Our results also point out a role of the mitochondria in this process. Altogether, our data define the effects of ROS on β cell differentiation and open new perspectives to improve protocols of β cell generation.

Page generated in 0.0296 seconds